The evaluation of leukocytes in response to the in vitro testing of ventricular assist devices

Artificial Organs

Volumn 37, Issue 9, 2013, Pages 793-801

  Chan, Chris H H ^a,b   Hilton, Andrew ^b   Foster, Graham ^b   Hawkins, Karl M ^a   Badiei, Nafiseh ^a   Thornton, Catherine A ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b Institute of Life Science 2   (United Kingdom)

Author keywords

Flow cytometric assay; Leukocyte damage; Leukocyte derived microparticles; Ventricular assist devices

Indexed keywords

BLOOD; FIBER OPTIC SENSORS; LEFT VENTRICULAR ASSIST DEVICES; PUMPS; SCANNING ELECTRON MICROSCOPY;

FLOW CYTOMETRIC ASSAY; HAEMATOLOGY; IMPLANTABLE ROTARY BLOOD PUMP; IN-VITRO TESTING; LEUCOCYTE DAMAGE; LEUCOCYTE-DERIVED MICROPARTICLE; LEUCOCYTES; MICRO PARTICLES; VENTRICULAR ASSIST DEVICE;

ASSAYS;

ARTICLE; BLOOD PUMP; CENTRIFUGAL PUMP; CONTROLLED STUDY; FLOW CYTOMETRY; HEMODYNAMICS; IN VITRO STUDY; LEUKOCYTE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; VENTRICULAR ASSIST DEVICE;

FLOW CYTOMETRIC ASSAY; LEUKOCYTE DAMAGE; LEUKOCYTE-DERIVED MICROPARTICLES; VENTRICULAR ASSIST DEVICES;

ANIMALS; ANTIGENS, CD45; CATTLE; CELL-DERIVED MICROPARTICLES; FLOW CYTOMETRY; HEART-ASSIST DEVICES; HEMOLYSIS; LEUKOCYTE COUNT; LEUKOCYTES;

EID: 84890860534     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12161     Document Type: Article

References (27)

1. Krishnamani R, DeNofrio D, Konstam MA. Emerging ventricular assist devices for long-term cardiac support. Nat Rev Cardiol 2010;7:71-76.
2. Hampton CR, Verrier ED. Systemic consequences of ventricular assist devices: alterations of coagulation, immune function, inflammation, and the neuroendocrine system. Artif Organs 2002;11:902-908.
3. Malehsa D, Meyer AL, Bara C, et al. Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate 2 ventricular assist device. Eur J Cardiothorac Surg 2009;35:1091-1093.
4. Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010;3:675-681.
5. Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist devices (HeartMate 2). J Am Coll Cardiol 2009;53:2162-2167.
6. Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circ J Am Assoc 2012;125:3038-3047.
7. Meyer AL, Kuehn C, Weidemann J, et al. Thrombus formation in a HeartMate left ventricular assist device. J Thorac Cardiovasc Surg 2008;135:203-204.
8. Holman WL, Rayburn BK, McGiffin DC, et al. Infection in ventricular assist devices: prevention and treatment. Ann Thorac Surg 2003;75:S48-57.
9. Synder TA, Litwak KL, Tsukui H, et al. Leukocyte-platelet aggregates and monocytes tissue factor expression in bovine implanted with ventricular assist devices. Artif Organs 2007;31:126-131.
10. Freedman JE, Loscalzo J. Platelet-monocyte aggregates bridging thrombosis and inflammation. Circulation 2002;105:2130-2132.
11. Shive MS, Salloum ML, Anderson JM. Shear stress-induced apoptosis of adherent neutrophils: a mechanism for persistence of cardiovascular device infections. PNAS 2000;97:6710-6715.
12. Diehl P, Aleker M, Heibing T, et al. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation. Interact Cardiovasc Thorac Surg 2010;11:133-137.
13. ASTM. F1830-97: Standard Practice for Selection of Blood for In Vitro Evaluation of Blood Pumps, 2005.
14. ASTM. F1830-97: Standard Practice for Assessment of Haemolysis in Continuous Flow Blood Pumps, 2005.
15. Chris HH, Chan HA, Foster G, et al. Re-evaluation of the Harboe assay as a standardized method of assessment for the hemolytic performance of ventricular assist devices. Artif Organs 2012;36:724-730.
16. Ryan EA, Mockros LF, Weisel JW, et al. Structural origins of fibrin clot Rheology. Biophys J 1999;77:2813-2826.
17. Bakir I, Hoylaerts MF, Kink T, et al. Mechanical stress activates platelets at a subhemolysis level: an in vitro study. Artif Organs 2007;31:316-323.
18. Hazarika B. What is missed in an automated cell count? Blood 2012;120:3394.
19. Snyder TA, Tsukui H, Kihara S, et al. Preclinical biocompatibility assessment of the EVAHEART ventricular assist device: coating comparison and platelet activation. J Biomed Mater Res A 2007;81:85-92.
20. Synder TA, Watach MJ, Litwak KN, et al. Platelet activation, aggregation, and life span in calves implanted with axial flow ventricular assist devices. Ann Thorac Surg 2002;73:1933-1938.
21. Sobieski MA, Giridharan GA, Ising M, et al. Blood trauma testing of CentriMag and RotaFlow centrifugal flow devices: a pilot study. Artif Organs 2012;36:677-682.
22. Nosé Y. Design and development strategy for the rotary blood pump. Artif Organs 1998;22:438-446.
23. James NL, Wilkinson CM, Lingard NL, et al. Evaluation of hemolysis in the VentrAssist implantable rotary blood pump. Artif Organs 2003;27:108-113.
24. Paul R, Apel J, Klaus S, et al. Shear stress related blood damage in laminar coquette flow. Artif Organs 2003;27:517-529.
25. Gilles C, Alain S, Benedicte H, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006;26:2775-2780.
26. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. PNAS 2010;107:15880-15885.
27. Borissoff JL, Ten Cate H. From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost 2011;9:1791-1794.